Protagonist Therapeutics Stock News

Regulatory and pipeline updates from Gilead (GILD) and Axsome (AXSM) are a few key highlights from the biotech sector during the past week.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Protagonist's Ulcerative Colitis Study Disappoints With Higher Dose Of PN-943 Protagonist Therapeutics

Protagonist Therapeutics Inc (NASDAQ: PTGX) announced topline results from the Phase 2 IDEAL study of PN-943 in moderate-to-severe ulcerative colitis (UC) patients. 159 patients with moderate-to-se

Shares of Protagonist Therapeutics Inc. PTGX, -0.58% tumbled 30.8% in premarket trading on Tuesday the day after the company said a Phase 2 clinical trial that gave patients a higher dose of its exper

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer-BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Ages 5-11 Pfizer Inc (

Protagonist Therapeutics Inc (NASDAQ: PTGX) received a letter from the FDA indicating the agency's intent to rescind Breakthrough Therapy Designation for the company's rusfertide product candidate

Protagonist Therapeutics (NASDAQ: PTGX ) has received a $25 million milestone payment from its collaboration with Janssen Biotech Inc , a unit of Johnson & Johnson (NYSE: JNJ ). The payment comes after the dosing of the third patient in the Phase 2b FRONTIER 1 clinical trial of PN-235 (JNJ-77242113). FRONTIER 1 is a Phase 2b … Full story available on Benzinga.com

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 2.53% and 16.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

NEWARK, Calif., Feb. 28, 2022 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. "This past quarter and the year leading up…

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 2.53% and 16.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

In last trading session, Protagonist Therapeutics Inc. (NASDAQ:PTGX) saw 0.54 million shares changing hands with its beta currently measuring 2.28. Company’s recent per share price level of $24.49 trading at $0.24 or 0.99% at ring of the bell on the day assigns it a market valuation of $1.20B. That closing price of PTGX’s stock is … Protagonist Therapeutics Inc. (NASDAQ:PTGX) Is Likely To Perform Well Over The Long Term. Lost Nearly -13.83% Last Month. Read More »

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 50.77% and 21.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

Protagonist Therapeutics (PTGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in t

Protagonist Therapeutics (PTGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in t